Free Trial

Cidara Therapeutics (CDTX) Competitors

Cidara Therapeutics logo
$88.58 +15.09 (+20.53%)
Closing price 04:00 PM Eastern
Extended Trading
$87.93 -0.65 (-0.73%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CDTX vs. RYTM, ABVX, CYTK, LEGN, AXSM, NUVL, RNA, MRUS, CRSP, and TGTX

Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), Merus (MRUS), CRISPR Therapeutics (CRSP), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

Cidara Therapeutics vs. Its Competitors

Cidara Therapeutics (NASDAQ:CDTX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

35.8% of Cidara Therapeutics shares are held by institutional investors. 7.6% of Cidara Therapeutics shares are held by insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cidara Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500.

Cidara Therapeutics currently has a consensus price target of $105.43, indicating a potential upside of 19.02%. Rhythm Pharmaceuticals has a consensus price target of $104.50, indicating a potential upside of 7.83%. Given Cidara Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cidara Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cidara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Rhythm Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
3.07

Cidara Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Cidara Therapeutics' return on equity of -50.81% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cidara TherapeuticsN/A -50.81% -42.46%
Rhythm Pharmaceuticals -117.13%-1,831.43%-48.33%

In the previous week, Cidara Therapeutics and Cidara Therapeutics both had 14 articles in the media. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Cidara Therapeutics' score of 0.71 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cidara Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rhythm Pharmaceuticals
10 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cidara Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cidara Therapeutics$1.27M1,768.81-$169.83M-$11.13-7.96
Rhythm Pharmaceuticals$130.13M49.46-$260.60M-$3.01-32.20

Summary

Cidara Therapeutics beats Rhythm Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Cidara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDTX vs. The Competition

MetricCidara TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.25B$3.11B$5.74B$10.35B
Dividend YieldN/A2.36%5.53%4.58%
P/E Ratio-7.9620.9076.3526.43
Price / Sales1,768.81254.49466.9890.96
Price / CashN/A46.3537.4661.85
Price / Book5.949.8313.186.39
Net Income-$169.83M-$52.73M$3.29B$271.22M
7 Day Performance36.59%4.85%2.50%2.79%
1 Month Performance33.46%6.37%4.60%7.35%
1 Year Performance722.47%19.15%73.81%29.74%

Cidara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDTX
Cidara Therapeutics
3.9207 of 5 stars
$88.58
+20.5%
$105.43
+19.0%
+576.1%$2.25B$1.27M-7.9690News Coverage
Analyst Forecast
Gap Up
High Trading Volume
RYTM
Rhythm Pharmaceuticals
3.4833 of 5 stars
$96.03
-0.2%
$101.57
+5.8%
+93.3%$6.39B$156.29M-31.90140Positive News
Analyst Forecast
ABVX
Abivax
2.5619 of 5 stars
$85.87
+2.2%
$99.43
+15.8%
+655.2%$6.35BN/A0.0061Gap Up
CYTK
Cytokinetics
4.222 of 5 stars
$49.44
-3.3%
$75.38
+52.5%
-6.8%$6.12B$18.47M-9.69250Trending News
Analyst Forecast
Analyst Revision
LEGN
Legend Biotech
3.1558 of 5 stars
$33.88
+2.3%
$74.22
+119.1%
-28.3%$6.11B$627.24M-38.502,609Positive News
AXSM
Axsome Therapeutics
4.8911 of 5 stars
$116.78
-1.4%
$177.86
+52.3%
+29.1%$5.91B$495.03M-23.03380Positive News
Insider Trade
NUVL
Nuvalent
3.1071 of 5 stars
$79.37
-1.4%
$120.91
+52.3%
-20.5%$5.80BN/A-16.2040
RNA
Avidity Biosciences
2.0524 of 5 stars
$40.22
-10.1%
$68.94
+71.4%
-2.8%$5.76B$10.90M-11.30190Analyst Forecast
MRUS
Merus
3.1658 of 5 stars
$68.09
-2.1%
$88.75
+30.3%
+42.8%$5.26B$36.13M-12.3837Positive News
CRSP
CRISPR Therapeutics
3.1896 of 5 stars
$57.84
+2.8%
$71.60
+23.8%
+30.0%$5.12B$37.31M-10.65460Analyst Forecast
TGTX
TG Therapeutics
4.3521 of 5 stars
$31.75
-1.3%
$46.25
+45.7%
+53.0%$5.10B$454.07M85.81290

Related Companies and Tools


This page (NASDAQ:CDTX) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners